INTRODUCTION: More than 30 years have passed since the amyloid-b precursor protein (APP) was identified. Although the role of APP in Alzheimer's disease has been studied widely, its normal physiological function in the brain has remained elusive. APP undergoes ectodomain shedding by a-, b-, or h-secretase to release secreted APP (sAPPa, sAPPb, or sAPPh, respectively). sAPPa affects synaptic transmission and plasticity and is sufficient to rescue synaptic defects in App knockout mice. This has led to speculation of a yet unidentified cell-surface receptor for sAPPa.
RATIONALE:
To elucidate the physiological function of APP, we sought to identify the cellsurface receptor mediating its effects on synaptic function. To identify candidate synaptic interactors for sAPPa, we performed affinitypurification experiments using recombinant sAPPa to pull down interacting proteins from synaptosome extracts, followed by mass spectrometric analysis of bound proteins. We identified the g-aminobutyric acid type B receptor (GABA B R), the metabotropic receptor for the inhibitory neurotransmitter g-aminobutyric acid (GABA), as the leading candidate for a synaptic, cell-surface receptor for sAPPa. We then performed a combination of cell-surface binding assays and in vitro biophysical techniques to determine the interacting domains and structural consequences of binding. We investigated whether sAPPa can modulate GABA B R function by assessing miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs, respectively) and synaptic vesicle recycling in mouse hippocampal neuron cultures, short-term plasticity in acute hippocampal slices from mice, and in vivo neuronal activity in the hippocampus of anesthetized mice.
RESULTS: Recombinant sAPPa selectively bound to GABA B R subunit 1a (GABA B R1a)-expressing cells. Binding was mediated by the flexible, partially structured extension domain in the linker region of sAPP and the natively unstructured sushi 1 domain specific to GABA B R1a. sAPPb and sAPPh, which both contain the extension domain, also bound to GABA B R1a-expressing cells. Conversely, APP family members APP-like proteins 1 and 2, which lack a conserved extension domain, failed to bind GABA B R1a-expressing cells. Acute application of sAPPa reduced the frequency of mEPSCs and mIPSCs and decreased synaptic vesicle recycling in cultured mouse hippocampal neurons. In addition, sAPPa enhanced short-term facilitation in acute hippocampal slices from mice. Together, these findings demonstrate that sAPP reduces the release probability of synaptic vesicles. These effects were dependent on the presence of the extension domain in sAPP and were occluded by a GABA B R antagonist. A short APP peptide corresponding to the GABA B R1a binding region within APP stabilized the natively unstructured sushi 1 domain of GABA B R1a, allowing determination of its solution structure using nuclear magnetic resonance spectroscopy and the generation of a structural model of the APP-sushi 1 complex. Application of a 17-amino acid APP peptide mimicked the effects of sAPPa on GABA B R1a-dependent inhibition of synaptic vesicle release and reversibly suppressed spontaneous neuronal activity in vivo.
CONCLUSION:
We identified GABA B R1a as a synaptic receptor for sAPP and revealed a physiological role for sAPP in regulating GABA B R1a function to modulate synaptic transmission and plasticity. Our findings provide a potential target for the development of GABA B R1a isoform-specific therapeutics, which is relevant to a number of neurological disorders in which GABA B R signaling is implicated. 
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sAPP is a functional GABA B R1a-specific ligand. In the presence of sAPP (right), the extension domain (ExD) of sAPP binds the sushi 1 domain specific to GABA B R1a. Binding induces a conformational change in the sushi 1 domain and leads to increased short-term facilitation and decreased neuronal activity via inhibition of neurotransmitter release. N, amino terminus; C, carboxyl terminus; a, b, and g, G protein subunits coupled to GABA B R subunit 2 (GABA B R2); E1 and E2, sAPP domains. A myloid-b precursor protein (APP), a type 1 transmembrane protein, was first identified more than 30 years ago (1) (2) (3) (4) as the precursor to the amyloid-b (Ab) peptide, the primary constituent of amyloid plaques found in the brains of Alzheimer's disease (AD) patients. APP undergoes ectodomain shedding by a-, b-, or h-secretase to release secreted APP (sAPPa, sAPPb, or sAPPh, respectively) (5, 6). Evidence suggests that the synaptic function of APP (7-13) is carried out by sAPP (14, 15) . sAPPa affects synaptic transmission and plasticity, including a reduction in synaptic activity and an enhancement of long-term potentiation (LTP) (16) (17) (18) (19) . Moreover, sAPPa is sufficient to rescue synaptic defects in App knockout (KO) mice, including defects in spine density (20) , LTP (21, 22) , and spatial learning (21) . Together, this has led to speculation of a yet-unidentified cell-surface receptor for sAPP to mediate its synaptic function (15, 23, 24) .
Proteomics screen for synaptic interactors of sAPP identifies GABA B R We first confirmed, using biochemical fractionation and structured illumination imaging, that APP was abundantly expressed at presynaptic terminals (25) of excitatory and inhibitory hippocampal synapses ( fig. S1, A and B) . Next, to identify candidate synaptic receptors for sAPP, we performed an extensive series of affinity-purification experiments using recombinant sAPP-Fc [C-terminal Fc tag; affinity purified from transfected-human embryonic kidney (HEK) 293T cell supernatants; fig. S2 , A and B] to pull down interacting proteins from synaptosome extracts, followed by mass spectrometric analysis of bound proteins [affinity purification-mass spectrometry (AP-MS)] (Fig. 1A ) (26) . We consistently identified, among a few intracellular proteins ( Fig. 1B; fig. S3 , A and B; and table S1), the g-aminobutyric acid type B receptor subunit 1 (GABA B R1) as the most abundant and reproducible cell-surface protein, using sAPPa or sAPPb as bait, in wild-type (WT) and in App/ Aplp1 (APP-like protein 1) double KO synaptosome extracts ( Fig. 1B; fig. S3 , A and B; and table S1). Supporting our observations, APP has previously been identified in a GABA B R interactome analysis (27) . Together, the sAPP AP-MS experiments identified GABA B R as the leading candidate for a synaptic, cell-surface receptor for sAPP.
The extension domain of APP binds the sushi 1 domain of GABA B R1a
GABA B R, the metabotropic receptor for the inhibitory neurotransmitter g-aminobutyric acid (GABA), regulates presynaptic neurotransmitter release and postsynaptic membrane excitability (28) . It consists of two subunits: GABA B R1, which binds GABA, and GABA B R2, which couples to G proteins (29) . Two major isoforms, GABA B R1a and GABA B R1b, differ by two N-terminal sushi repeats only present in the a-variant (29) (Fig. 1C) . To validate the proteomics results, we performed cell-surface binding assays, applying recombinant sAPPa-Fc to HEK293T cells expressing the GABA B R ectodomain on the plasma membrane using the pDisplay vector. sAPPa-Fc, but not Fc alone, bound strongly to GABA B R1a-expressing cells, but not to GABA B R1b-or GABA B R2-expressing cells (Fig. 1D ). Biolayer interferometry experiments using recombinant sAPPa (Fc tag enzymatically removed; fig. S2 , C to F) and GABA B R1a sushi domains showed that the sushi 1 peptide was sufficient for binding sAPPa (Fig. 1E) . Accordingly, excess sushi 1 peptide blocked binding of sAPPa-Fc to GABA B R1a-expressing cells (Fig. 1F) . Isothermal titration calorimetry (ITC) determined the dissociation constant (K D ) for sAPPa-sushi 1 to be 431 nM (Fig. 1G) . Thus, sAPPa binds directly and selectively to the sushi 1 domain of GABA B R1a with submicromolar affinity.
The ectodomain of the APP695 isoform of APP contains several functional domains ( Fig. 2A) . Surprisingly, growth factor-like domain (GFLD)-Fc, copper binding domain (CuBD)-Fc, and E2-Fc each failed to bind GABA B R1a-expressing cells (Fig. 2B ). However, a peptide corresponding to the natively unstructured linker region between the APP695 E1 and E2 domains ( Fig. 2A ) strongly bound to GABA B R1a-expressing cells (Fig. 2B ). The linker region includes the acidic domain (AcD) and the recently defined extension domain (ExD), which is a flexible, partially structured region (30) . The binding affinity of the purified ExDAcD fragment (Fc tag enzymatically removed) to sushi 1 in ITC experiments ( Fig. 2C ) was in the same range as that of full-length sAPPa binding to sushi 1 (Fig. 1G ). To further narrow down the minimal domain in the APP linker region required for sushi 1 binding, we generated ExD-Fc and AcD-Fc fragments. ExD-Fc, but not AcD-Fc, bound to GABA B R1a-expressing cells (Fig.  2B ), identifying the ExD as the minimal domain required for sushi 1 binding. Consequently, deletion of the ExD in sAPPa (sAPPaDExD-Fc) abolished binding to GABA B R1a-expressing cells (Fig.  2B ). sAPPb-Fc and sAPPh-Fc, a product of the recently described h-secretase processing pathway (6), which both contain the ExD, also bound to GABA B R1a-expressing cells (Fig. 2D) . APP family members APP-like protein 1 and 2 (APLP1 and APLP2) (31) , on the other hand, lack a conserved ExD and failed to bind GABA B R1a-expressing cells (Fig. 2E) . Thus, the sAPP ExD is necessary and sufficient to bind to the GABA B R1a sushi 1 domain.
sAPP suppresses probability of presynaptic vesicle release via GABA B R1a
Sushi domain-containing GABA B R1a is the predominant isoform localized to presynaptic compartments at excitatory synapses (32) (33) (34) , where it functions to inhibit neurotransmitter release (28) . To test whether sAPPa can modulate GABA B R function, we simultaneously measured miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs, respectively), which were separated on the basis of their distinct decay kinetics as described (35) , in cultured mouse hippocampal neurons (12 to 17 days in vitro) (Fig.  3A) . Consistent with previous observations (36, 37), acute exposure of hippocampal neurons to 30 mM baclofen, a GABA B R agonist, reduced the frequency of mEPSCs by 63 ± 5% (n = 14 cells; P < 0.001) (fig. S4, A and B). Likewise, 250 nM sAPPa (Fc tag removed) reduced the frequency of mEPSCs by 39 ± 5% (n = 13 cells; P < 0.001) (Fig. 3 , B and C), an effect that was already apparent at 25 nM 2 of 7 . The number of total cells from three to five independent experiments is defined as n. Graphs show means ± SEM. Two-way (B) and (E) or one-way (D) ANOVA with Bonferroni's post hoc analysis was used; ***P < 0.001. Scale bars, 10 mm.
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ExD-AcD S4C ). sAPPb similarly reduced mEPSC frequency ( fig. S4, D and E) . Acute application of the APP695 ExD-AcD fragment reduced mEPSC frequency to a similar degree as sAPPa (Fig. 3D and fig. S4F ), whereas application of sAPPaDExD had no effect (Fig. 3D  and fig. S4F ), indicating that the ExD of sAPP is necessary and sufficient for the suppression of spontaneous glutamatergic synaptic transmission by sAPPa. Accordingly, acute application of sAPLP1, which lacks a conserved ExD, did not reduce mEPSC frequency ( fig. S4G) , although we observed a minor (17 ± 9%; n = 17 cells; P < 0.05) reduction in mIPSC frequency ( fig. S4H ). Pretreatment with the GABA B R antagonist CGP55845 (5 mM) attenuated the sAPPa-mediated reduction of mEPSC frequency (Fig. 3E and fig. S4I) , showing that the effect is mediated by GABA B R.
GABA B R1a also localizes to GABAergic boutons (34) . Consistent with previous observations (37, 38) , acute exposure of hippocampal neurons to 30 mM baclofen reduced the frequency of mIPSCs by 62 ± 5% (n = 14 cells; P < 0.001) ( fig. S5A ). Acute application of 250 nM sAPPa to hippocampal neurons reduced the frequency of mIPSCs by 44 ± 5% (n = 13 cells; P < 0.001) (Fig. 3B and fig.  S5B ). Application of sAPPa caused a minor (14%) reduction in mIPSC amplitude ( fig. S5C ), possibly owing to a small postsynaptic effect of sAPPa on GABA B R1a at postsynaptic GABAergic sites (39) . The APP695 ExD-AcD fragment, but not sAPPaDExD, reduced mIPSC frequency to a similar extent as sAPPa (figs. S4F and S5D). The effect of sAPPa on mIPSC frequency was blocked by pretreatment with the GABA B R antagonist CGP55845 (5 mM) (figs. S4I and S5E). Thus, sAPPa acutely reduces both glutamatergic and GABAergic quantal synaptic transmission through a GABA B R1a isoform-dependent mechanism.
sAPPa might exert its effect on synaptic transmission by interfering with a complex of fulllength APP and GABA B R1a. In neurons lacking APP, however, sAPPa still reduced mEPSC and mIPSC frequency ( fig. S6, A and B) , excluding this possibility. Application of 30 mM baclofen similarly reduced mEPSC and mIPSC frequency in App/Aplp1 double KO cultures ( fig. S6 , C and D) as in WT cultures (Fig. 3C and fig. S5B ), suggesting that the absence of full-length APP does not cause major alterations in GABA B R localization to presynaptic terminals. However, the possibility that full-length APP also interacts with and affects GABA B R signaling separate from the effects of sAPPa reported here cannot be excluded.
The decrease in mEPSC frequency, but not amplitude, following acute sAPPa application suggests a change in presynaptic release properties. We therefore assessed the effect of sAPPa on presynaptic vesicle recycling using the fluorescent membrane dye FM1-43. We measured presynaptic strength by measuring the density (D) of FM1-43-positive boutons per image area and the change in fluorescence intensity (DF) of FM1-43 signals at individual boutons of cultured hippocampal neurons using a combined FM1-43 loading-unloading stimulation paradigm (Fig.  3F) . Application of sAPPa decreased the total presynaptic strength (S = DF × D) across synaptic populations (Fig. 3G and fig. S7A ) in a dosedependent manner (Fig. 3H) , reaching 57 ± 7% (n = 8 experiments; P < 0.001) reduction at 1 mM sAPPa. This decrease was not observed with deletion of the ExD (sAPPaDExD, 1 mM) (Fig. 3H  and fig. S7B ) and was occluded by the GABA B R antagonist CGP54626 (10 mM) (Fig. 3I and fig.  S7C ), indicating that GABA B R1a mediates the presynaptic inhibition induced by sAPPa.
sAPP enhances short-term plasticity at Schaffer collateral synapses in a GABA B R1a-dependent manner
We next assessed the effect of sAPPa on synaptic transmission in an intact circuit at CA3-CA1 Schaffer collateral (SC) synapses, which exclusively contain GABA B R1a receptors (32) . We measured field excitatory postsynaptic potentials (fEPSPs) evoked by low-frequency stimulation (0.1 Hz) at varying intensities (30 to 150 mA) in CA1 stratum radiatum after 90 min preincubation of acute hippocampal slices with or without 1 mM sAPPa (Fig. 4A) . Treatment with sAPPa reduced fEPSP amplitude and decreased the slope of the input-output (i-o) curve by 23% ( fig.  S8A ), indicating that sAPPa suppresses basal synaptic transmission at SC synapses. To specifically assess if sAPPa affects presynaptic properties, we applied a burst of five stimuli at three different frequencies (20, 50 , and 100 Hz) to induce shortterm facilitation, which inversely correlates with the probability of neurotransmitter release. Facilitation was higher for each frequency tested in sAPPa-incubated slices compared with control slices (Fig. 4B and fig. S8, B and C) . Analysis of the paired-pulse ratio (PPR) for the first two The number of slices is defined as n, and the number of independent experiments or mice is defined as N. Graphs show means ± SEM. Two-way ANOVA analysis was used. *P < 0.05; **P < 0.1; ns, not significant. 's t test) . Dotted line indicates baseline.The number of neurons is defined as n, and the number of independent experiments is defined as N. Graphs show means ± SEM. ***P < 0.001; ns, not significant. stimuli showed an increased PPR for each frequency after sAPPa treatment (Fig. 4C) , indicating a decreased release probability. Deletion of the ExD (sAPPaDExD, 1 mM) abolished the sAPPa-mediated effect on the i-o curve ( fig. S9D ), short-term facilitation (Fig. 4D and fig. S8 , E and F), and PPR (Fig. 4E ). In addition, preincubation of slices with the GABA B R antagonist CGP54626 (10 mM) abolished the sAPPa-mediated decrease in the slope of the i-o curve ( fig. S8G ) and occluded the sAPPa-induced increase in shortterm facilitation and PPR at each frequency (Fig. 4, F and G, and fig. S8 , H and I), demonstrating the GABA B R-dependence of these effects. Thus, sAPPa controls vesicle release at SC synapses by acting on presynaptic GABA B R1a.
A short peptide within the APP ExD suppresses synaptic vesicle release via GABA B R1a
A GABA B R1a isoform-specific modulator has potential therapeutic implications for a number of neurological disorders involving GABA B R signaling (29) . Because we observed that purified protein corresponding to the linker region of APP ( Fig. 2A) was sufficient to mimic the effects of sAPPa on mEPSC frequency (Fig. 3D) , we set out to identify the minimally active region within the ExD. Alignment of the sAPP ExD [amino acid residues 195 to 227 of APP695] from seven vertebrate species revealed the strongest conservation within a 17-amino acid stretch (residues 204 to 220; Fig. 5A ). The corresponding synthetic APP 17-mer peptide bound sushi 1 of GABA B R1a with a K D of 810 nM (Fig. 5B) , in the same range as the binding affinity of the entire linker region (Fig. 2C) . Shortening the peptide to a synthetic 9-mer consisting of APP695 residues 204 to 212 (APP 9-mer) lowered the K D to 2.3 mM (Fig.  5C ), whereas residues 211 to 220 failed to bind sushi 1 ( fig. S9A ). Thus, a conserved, minimal 9-amino acid sequence within the sAPP ExD is sufficient for direct binding to the sushi 1 domain of GABA B R1a.
To gain further insight into the binding of the APP 9-mer to the GABA B R1a sushi 1 domain, we used nuclear magnetic resonance (NMR) spectroscopy. As previously reported (40), we observed that the sushi 1 domain of GABA B R1a is natively unstructured ( fig. S9B) . Notably, APP 9-mer binding stabilized the sushi 1 domain of GABA B R1a, allowing determination of its solution structure ( Fig. 5D and fig. S9C ) and generation of a structural model of the complex (Fig. 5E ). In our model, valine and tryptophan at residues 208 and 209, respectively, of APP695 bind within a pocket of sushi 1, formed by the loops and the short b strand in the N-terminal part of the protein (residues 32 to 53 of full-length GABA B R1a) ( fig. S9D) . Thus, APP binding induces a conformational change in the natively unstructured sushi 1 domain of GABA B R1a. This structure-function relationship strongly supports the physiological relevance of the interaction.
Because the affinity for sushi 1 was better retained in the APP 17-mer compared with the 9-mer (Fig. 5, B and C) , we next tested whether the APP 17-mer could functionally mimic sAPPa. Acute application of the APP 17-mer peptide, but not of a scrambled 17-mer control peptide, reduced mEPSC frequency in hippocampal neurons to a similar degree as sAPPa ( Fig. 5F and fig. S9E ) and was already apparent at 25 nM ( fig. S9F ). Pretreatment with the GABA B R antagonist CGP55845 (5 mM) blocks this effect (Fig. 5G and fig. S9G ).
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Together, these findings show that the APP 17-mer peptide mimics the effects of sAPPa on GABA B R1a-dependent inhibition of synaptic vesicle release.
APP 17-mer peptide suppresses neuronal activity of CA1 pyramidal cells in vivo
In the final series of experiments, we used the APP 17-mer peptide as a tool to examine the effects of sAPP-GABA B R signaling on neuronal activity in vivo. Using two-photon calcium imaging, we measured calcium transients of CA1 hippocampal neurons in anesthetized transgenic mice expressing the genetically-encoded calcium indicator GCaMP6s under the Thy-1 promoter (Thy1-GCaMP6s) before (baseline) and after a 60 to 90 min superfusion of the exposed hippocampus with either baclofen (30 mM), APP 17-mer (5 mM), or scrambled 17-mer control peptide (5 mM) (Fig.  6A) . Application of 30 mM baclofen caused a dramatic decrease in the frequency of calcium transients compared to baseline ( fig. S10 , A to C), indicating that activation of GABA B Rs strongly suppresses neuronal activity in CA1 pyramidal neurons in vivo. Consistent with our results in cultured hippocampal neurons, application of the APP 17-mer significantly reduced the frequency of calcium transients compared to baseline (Fig. 6 , B to D, and movie S1). The frequency of calcium transients was restored back to baseline after a 2-hour wash-out of the peptide ( fig. S10 , D to F), indicating that the suppression of CA1 neuron activity by the APP 17-mer peptide is reversible. Furthermore, the scrambled 17-mer control peptide did not affect the frequency of calcium transients (Fig. 6, E to G; fig. S10 , G to I; and movie S2). Thus, APP inhibits neuronal activity in vivo, and the GABA B R1a binding domain is sufficient for such inhibition.
Discussion
Here, we found that sAPP acts as a GABA B R1a-specific ligand to suppress synaptic vesicle release. Consequently, sAPP modulates hippocampal synaptic plasticity and neurotransmission in vivo. APP is among the most abundant proteins in synaptic boutons (25) , and deletion of App in mice leads to synaptic deficits (7-9, 21, 22) . Synaptic activity enhances proteolytic processing of APP (41, 42) , and GABA B R is a key regulator of homeostatic synaptic plasticity (43) . Our observations raise the possibility that the sAPP-GABA B R1a interaction acts as an activity-dependent negative-feedback mechanism to suppress synaptic release and maintain proper homeostatic control of neural circuits. Although AD-causing mutations in APP all affect Ab generation, it is not entirely clear whether other aspects of APP function contribute to AD. Network abnormalities such as hyperexcitability and hypersynchronization precede clinical onset of AD in human patients (44) . Some studies indicate that sAPP levels may be altered in AD (14) . Interestingly, a GABA B R antagonist can improve memory in animal models and patients with mild cognitive impairment (45) (46) (47) . Moreover, because most transgenic AD mouse models overexpress sAPP, the role of sAPP in synaptic phenotypes of transgenic APP mice should be considered, particularly given evidence that network hyperexcitability in these mice is independent of Ab production (48) . GABA B R signaling has been implicated in a number of neurological and psychiatric disorders, including epilepsy, depression, addiction, and schizophrenia (49) . Selective binding partners of the GABA B R1a sushi domains are of potential therapeutic interest owing to localization and functional differences of GABA B R1 isoforms (32, 50) as well as the adverse effects of current nonspecific agonists (29) . The identification of sAPP as a functional GABA B R1a-specific binding partner provides a target for the development of therapeutic strategies for modulating GABA B R1a-specific signaling in neurological and psychiatric disorders. The identification of short APP peptides that confer structure in the GABA B R1a sushi 1 domain and modulate neurotransmission in vivo are major steps toward development of a GABA B R1a isoform-specific therapeutic.
Methods summary
To identify candidate synaptic interactors for sAPP, affinity-purification experiments were performed using recombinant sAPP-Fc to pull down interacting proteins from synaptosome extracts, followed by MS analysis of bound proteins. Cellsurface binding assays, biolayer interferometry, and ITC were used to determine domains of interaction and apparent binding affinities between sAPP and GABA B R. NMR spectroscopy was used to generate a structural model of the APP-GABA B R complex. The function of the sAPP-GABA B R interaction was investigated by accessing spontaneous postsynaptic currents and FM1-43 dye labeling in mouse hippocampal cultures, short-term facilitation in acute hippocampal slices, and two-photon in vivo calcium imaging in CA1 hippocampus of anesthetized Thy1-GCaMP6 mice. The details of each of these methods are described in the supplementary materials.
